Sertio Oy
Biokatu 10
33520 Tampere
Finland

5.8.2025

Notified Body Confirmation Letter

Reference: 800035 (customer ID)

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2024/1860 amending Regulations (EU) 2017/746 as regards the transitional provisions for certain in vitro diagnostic medical devices.

This letter confirms that, Sertio Oy, a Notified Body (NB) designated against Regulation (EU) 2017/746 (IVDR) and identified by the number 3018 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of IVDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of IVDR with the following manufacturer:

Jiangsu Medomics Medical Technology Co.,Ltd.
Building 01, Phase 6, No.71, Xinghui Road, Jiangbei New Area,
Nanjing, 210000, Jiangsu,
P.R. China

SRN Number (if available): CN-MF-000030226

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an IVDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the Directive 98/79/EC.

Table 2 identifies the devices for which an IVDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the Directive 98/79/EC.

In the case of devices covered by certificates issued under Directive 98/79/EC (IVDD) that expired after 26 May 2022 and before 09 July 2024, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under IVDR by the date of IVDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 54 of IVDR or Article 92 of the IVDR respectively, by the 09 July 2024 for the relevant devices. The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 110.3c of IVDR (as amended by (EU) 2024/1860), are shown below:

- 31 December 2027 for devices covered by an IVDD certificate regardless of their risk class under the IVDR
- For devices not requiring the involvement of a notified body under the IVDD, but requiring it under the IVDR and for which a declaration of conformity was drawn up prior to 26 May 2022 in accordance with Directive 98/79/EC, the following dates apply:
  - 31 December 2027, for class D devices;
  - 31 December 2028, for class C devices;
  - 31 December 2029, for class B devices and for class A devices placed on the market in sterile condition

On behalf of the Notified Body,

Mikko Soikkeli
Deputy Head of the Notified Body 3018
Notified Body 3018
Biokatu 10, 33520 Tampere, Finland
info@sertio.fi
www.sertio.fi

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under Directive 98/79/EC:

Device name or Basic UDI-DI (under IVDR application)	**IVDR Device classification (as proposed by the manufacturer and verified at the preapplication stage)**	**If the IVDR device is a substitute device, identification of the corresponding IVDD device**	**IVDD/ Certificate Reference(s) of the devices under IVDR application, and the NB Identification**
SARS-CoV-2 & Influenza A/B Antigen Combo Rapid Test Kit (LFIA)	*Class C*	*N/A*	*Certificate#: 1434-IVDD-193/2022 NB#: 1434(POLSKIE CENTRUM BADAN I CERTYFIKACJI S.A.)*
SARS-CoV-2 Antigen Test Kit (LFIA)	*Class C*	*N/A*	*Certificate#: 1434-IVDD-194/2022 NB#:1434(POLSKIE CENTRUM BADAN I CERTYFIKACJI S.A.)*

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under Directive 98/79/EC:

Device name or Basic UDI-DI (under IVDR application)	**IVDR Device classification (as proposed by the manufacturer and verified at the preapplication stage)**	**If the IVDR device is a substitute device, identification of the corresponding IVDD device**	**IVDD/ Certificate Reference(s) of the devices under IVDR application, and the NB Identification**
SARS-CoV-2/FluA/FluB+ADV/RSV/SA Antigen Combo Rapid Test Kit (LFIA)	*Class B*	*N/A*	*N/A Device did not require a Notified Body certificate under Directive*

Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
5.8.2025	800035-CL-1	Initial issue